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Buruli ulcer is a neglected infectious disease caused by Mycobacterium ulcerans and is characterized by
necrotic cutaneous lesions induced by the exotoxin mycolactone. Despite evidence of Th1-mediated protective
immunity, M. ulcerans infection has been associated with systemic immunosuppression. We show that early
during mouse infection with either mycolactone-positive or negative strains, pathogen-speciﬁc gamma inter-
feron (IFN-)-producing T cells developed in the draining lymph node (DLN). CD4 cells migrated to the
infection foci, but progressive infection with virulent M. ulcerans led to the local depletion of recruited cells.
Moreover, dissemination of virulent M. ulcerans to the DLN was accompanied by extensive DLN apoptotic
cytopathology, leading to depletion of CD4 T cells and abrogation of IFN- expression. Advanced footpad
infection with virulent M. ulcerans did not induce increased susceptibility to systemic coinfection by Listeria
monocytogenes. These results show that infection with M. ulcerans efﬁciently triggers a mycobacterium-speciﬁc
T-cell response in the DLN and that progression of infection with highly virulent M. ulcerans leads to a local
and regional suppression of that immune response, but without induction of systemic immunosuppression.
These results suggest that prophylactic and/or therapeutic interventions to prevent dissemination of M.
ulcerans to DLN during the early phase of infection would contribute for the maintenance of protective
immunity and disease control.
Buruli ulcer (BU) is an emerging neglected tropical disease
caused by Mycobacterium ulcerans and is characterized by non-
ulcerative lesions that can evolve into severe ulcers (41, 70).
Infection by M. ulcerans poses a unique challenge for the
host immune system due to the secretion of the highly cytotoxic
lipidic exotoxin mycolactone (17). Mycolactone has been sug-
gested to suppress the development of local and systemic im-
mune responses by inhibiting cytokine production during ac-
tive BU (19–21, 42, 72, 75) and compromising T-cell priming
by suppressing dendritic cell function (11). However, there are
no studies on the association of BU with opportunistic infec-
tions, suggesting that the immunosuppressive effects of myco-
lactone might not be systemic.
The observations that active BU occurs in a small proportion
of exposed individuals (14, 58) and when it develops frequently
heals spontaneously (69) suggest the existence of protective
immunity. Although the protective mechanisms remain largely
unknown, several studies support that adaptive cell-mediated
immunity (CMI) is relevant for the control of M. ulcerans
(reviewed in reference 53). In fact, (i) M. ulcerans has an
intramacrophage growth phase (66), (ii) resistance to BU is
associated with the development of T helper (Th) 1 type re-
sponses and granulomata (10, 20, 21, 23, 42, 48, 63, 70, 72), (iii)
the positivity of the delayed-type hypersensitivity (DTH) bu-
rulin test increases from early to advanced phases (15, 31), (iv)
the histopathology of healing BU lesions in patients submitted
to antibiotic treatment is consistent with CMI (49), (v) Myco-
bacterium bovis BCG vaccination induces transient protection
in humans and in experimental infections (16, 55, 60, 62, 68),
(vi) infection with HIV increases the risk of developing BU
and more aggressive multifocal forms (27, 64), and (vii) the
pattern of cytokine expression in BU lesions conforms with
CMI and DTH (28, 38, 67).
Therefore, to clarify whether the M. ulcerans infectious pro-
cess interferes with the development of protective immunity
and whether systemic immunosuppression is induced, we mon-
itored the host immune response in the mouse model, not only
in the primary site of infection but also in the draining lymph
node (DLN), where the initiation of the adaptive immunity
takes place.
MATERIALS AND METHODS
Animals. Eight-week-old female wild-type, nude, and Rag2-deﬁcient mice in a
BALB/c background were obtained from Charles River (Barcelona, Spain).
Rag-deﬁcient BALB/c mice transgenic for the DO11.10 / T-cell receptor
(TCR) were from Anne O’Garra (NIMR, London, United Kingdom). The stud-
ies involving animals were approved by the review committees of ICVS and the
Portuguese Governmental Agency Direcc¸a˜o Geral de Veterina´ria.
Experimental infections. The different M. ulcerans strains used in the present
study were selected based on their virulence for mice (35, 65) and on the type of
mycolactone produced (26, 32, 59). M. ulcerans 5114 is a low-virulence Mexican
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isolate that does not produce mycolactone (32) due to the loss of key genes
involved in the synthesis of this macrolide (59). The Australian strain 94-1327
was isolated from an ulcer and produces the mycolactone C (32). Strain 97-1116
was isolated in Benin from a patient presenting with a plaque and was found to
produce mycolactones A and B (32); M. ulcerans 98-912 was isolated in China
from an ulcer and produces mycolactone D (26). All M. ulcerans strains used in
the present study are from the collection of the Institute of Tropical Medicine
(ITM), Antwerp, Belgium. The isolates were grown on solid Middlebrook 7H9
medium at 32°C for approximately 1 month.
For the preparation of M. ulcerans inoculum, bacteria were diluted in phos-
phate-buffered saline (PBS) and vortexed using glass beads. The number of
acid-fast bacilli (AFB) in inocula was determined by using Ziehl-Neelsen staining
(Merck) according to the method described by Shepard and McRae (50). For L.
monocytogenes strain EGD inocula, bacteria were grown in brain heart infusion
broth at 37°C to mid-log phase and frozen in aliquots at80°C. Mice were either
infected subcutaneously in the footpad with M. ulcerans (3  105 AFB) alone or
coinfected intravenously with L. monocytogenes (5  103 CFU).
Bacterial proliferation in footpad. M. ulcerans proliferation was evaluated in
footpad tissues of infected mice. Brieﬂy, tissue specimens were minced, resus-
pended in PBS containing 0.04% Tween 80 (Sigma), and vortexed with glass
beads. The number of AFB in the bacterial suspension was determined by using
the method of Shepard and McRae (50).
Flow cytometry. Single cell suspensions of the popliteal lymph nodes were
stained with a combinations of ﬂuorochrome-labeled monoclonal antibodies
speciﬁc for CD3 (clone 145-2C11), CD19 (clone 1D3), CD4 (clone RM4-5), CD8
(clone 53-6.7), CD62L (clone MEL-14), BrdU (clone PRB-1), and transgenic
DO11.10 TCR (KJ1-26). Cells were analyzed by using CellQuest software on a
Becton Dickinson FACSCalibur ﬂow cytometer.
Cell suspensions from infected footpads. Infected footpads were collected and
incubated in incomplete Dulbecco modiﬁed Eagle medium (DMEM; Gibco) and
125 U collagenase XI (Sigma-Aldrich)/ml, for 2 h at 37°C. Each footpad was
ﬁltered through a 40-m-pore-size nylon cell strainer and washed with DMEM
supplemented with 10% heat-inactivated fetal bovine serum (Sigma-Aldrich).
Real-time PCR. Cell suspensions from the DLN and the infected footpad were
frozen in TRIzol reagent (Invitrogen), and total RNA was extracted according to
the manufacturer’s protocol. Quantiﬁcation of message for ubiquitin and gamma
interferon (IFN-) was carried out with Sybr green (Qiagen). The sequences for
the ubiquitin and the IFN- reaction were designed and synthesized by TIB
MolBiol and were as follows: ubiquitin forward, GCTGGTGAAAAGGACC
TCT; ubiquitin reverse, CACAGGACTAGAACACCTGC; IFN- forward, TG
GCAAAAGGATGGTGACATG; and IFN- reverse, GACTCCTTTTCCGCT
TCCTGA. The primers and probes for Cxcl9, Cxcl10, and Cxcl11 were purchased
from Applied Biosystems gene expression assays.
ELISPOT assay. As previously described, the enzyme-linked immunospot
(ELISPOT) assay was used for the detection of antigen-speciﬁc IFN--producing
cells from infected DLN (13). Cells were stimulated with either 10 g of peptide
Ag85A/ml or 10 g of tuberculin PPD derivative of M. tuberculosis (Statens
Seruminstitut)/ml. The cells cultured in the absence of antigen or cells from
uninfected mice did not produce detectable spots.
Adoptive transfer. The adoptive transfer was performed as previously de-
scribed (7). Brieﬂy, splenocytes from DO11.10 TCR transgenic mice (106 trans-
genic CD4 T cells) were injected intravenously into uninfected mice or mice
that were infected for 1 week with M. ulcerans. Mice were primed 2 days after
adoptive transfer with 3 mg of ovalbumin (OVA; Sigma-Aldrich) subcutaneously
in the M. ulcerans-infected footpad.
T-cell turnover by BrdU incorporation. Bromodeoxyuridine (BrdU; 1 mg;
Sigma) was injected intraperitoneally into mice, twice a day, for 3 days prior
analysis. Cells were harvested from the DLN, labeled with anti-CD4 and anti-
KJ1.26, washed with PBS, and ﬁxed overnight at 4°C with 1% paraformaldehyde–
0.2% Tween 20. Cells were incubated with 50 U of DNase (Roche)/ml at 37°C for
1 h, washed with Coffman’s balanced salt solution–1% bovine serum albumin–
0.2% Tween 20, and stained with anti-BrdU (eBioscience) or ﬂuorescein iso-
thiocyanate isotype control for 45 min at 4°C before ﬂow cytometric analysis.
Bacterial load determination. The DLN, spleens, and livers were aseptically
excised and individually homogenized. Serial dilutions of the organ homogenate
were plated on nutrient 7H9 agar or brain heart infusion agar medium (Prona-
disa). M. ulcerans CFU was counted after 6 to 8 weeks of incubation at 32°C, and
the L. monocytogenes CFU were counted after 24 h of incubation at 37°C.
Histological and immunoﬂuorescence studies. DLN and footpads were har-
vested, ﬁxed in buffered formalin, and embedded in parafﬁn. Light-microscopy
studies were performed on tissue sections stained with hematoxylin and eosin
(H&E). For immunoﬂuorescence staining, antigen retrieval was performed with
citrate buffer (Lab Vision Corp.) for 30 min. Apoptotic cells were stained with
anti-human/mouse caspase-3 active (R&D) at 1:250 for 3 h at room temperature
and then incubated with Alexa Fluor 568 (Molecular Probes) for 1 h at room
temperature. For the detection of CD4 cells, the sections were incubated with
phycoerythrin-conjugated anti-CD4 (clone RM4-5; Santa Cruz Biotechnology)
at 1:50 overnight at 4°C. DAPI (4	,6	-diamidino-2-phenylindole) was used to
detect nuclei. Images were obtained with an Olympus BX61 microscope.
Statistical analysis. Differences between the means of experimental groups
were analyzed with the two-tailed Student t test. Differences with a P value of
0.05 were considered signiﬁcant.
RESULTS
T cells are required to control infection by low-virulence M.
ulcerans 5114. To understand the mechanisms underlying the
susceptibility of hosts to progressive infections by M. ulcerans,
we investigated whether T cells are involved in the host re-
sponse to this intracellular pathogen. For that, we infected
mice deﬁcient in the recombinase gene RAG-2 that results in
the lack of V(D)J recombination activity, TCR rearrangement,
and consequent inability to generate mature lymphocytes (51–
52) or nude mice that present a deteriorated or absent thymus,
also resulting in the inability to generate mature T lymphocytes
(39). During infection with the mycolactone-negative M. ulcer-
ans strain 5114, wild-type mice effectively controlled bacterial
proliferation in the footpad, whereas Rag2/ and nude mice
showed a 3-log10 increase in bacterial burdens (Fig. 1A and C).
In contrast, no differences were found in the proliferation of
the highly virulent strain 98-912 (Fig. 1B and D), regardless of
the presence of lymphocytes in the host. These data suggest a
role for T-cell-mediated responses in the control of infection
by a low-virulence M. ulcerans strain and in the failure of this
response to control infections by a mycolactone-producing
strain.
M. ulcerans induces an early accumulation of CD4 cells in
the DLN, regardless the strain virulence. We next evaluated
whether the lack of T-cell-dependent protection in mice in-
fected with M. ulcerans 98-912 was due to T-cell anergy (19–21)
or to mycolactone-mediated impairment of maturation/migra-
tion of dendritic cells and, consequently, T-cell activation (11).
Infection with strain 5114 induced an initial increase in the
total number of DLN cells to a level that was maintained
throughout the experimental infection (Fig. 2A). With the
mycolactone-producing strain 98-912, we observed a 27-fold
increase in the number of DLN cells during the ﬁrst 2 weeks,
followed by a sharp decrease (Fig. 2A). Analysis of the DLN
lymphocytic populations in mice infected with either M. ulcer-
ans strains revealed that both CD3 (Fig. 2B) and CD19
(Fig. 2C) cells followed the cellular dynamics described above,
with a predominance of the CD4 phenotype (Fig. 2D and E).
To investigate whether the host mounts antigen-speciﬁc
CD4 T-cell responses in the DLN during a progressive M.
ulcerans infection, we adoptively transferred OVA-speciﬁc
TCR transgenic cells (KJ1.26) to previously infected mice,
later challenged with the cognate antigen in the infected foot-
pad. Mice infected with either strain were not compromised in
their ability to initiate a T-cell response to OVA in the DLN,
since CD4KJ1.26 T-cell accumulation was increased com-
pared to uninfected controls (Fig. 3A). Consistent with the
occurrence of T-cell activation, CD62L was downregulated on
CD4KJ1.26 cells (Fig. 3B). Both T-cell accumulation and
activation were more pronounced in mice previously infected
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with M. ulcerans 98-912. Thus, the infectious process at the site
of antigen challenge did not compromise the initiation of cel-
lular immune responses. Moreover, the infection did not com-
promise the proliferative activity of DO11.10 CD4 cells in the
DLN (Fig. 3C). Altogether, these data indicate that early in-
fection by M. ulcerans does not compromise the development
of antigen-speciﬁc T-cell responses in the DLN.
Early during infection, highly virulent M. ulcerans induces
the development of IFN--producing pathogen-speciﬁc T cells
in the DLN. Given the onset of cellular immune responses in
the DLN, we questioned whether CD4 T cells were able to
mount a mycobacterium-speciﬁc Th1 immune response. Cor-
relating with T-cell dynamics (Fig. 2B), we found a moderate
increase in the expression of IFN- mRNA that was main-
tained during infection with strain 5114, while infection with
strain 98-912 induced a higher peak of IFN- expression at day
15, followed by a sharp decline (Fig. 4A). To assess whether
the increased expression of IFN- was associated to generation
of mycobacterium-speciﬁc T cells in the DLN, the frequency of
IFN--producing T cells responding to the mycobacterial an-
tigens Ag85A (Fig. 4B) or PPD (data not shown) was deter-
mined by ELISPOT assay at day 14 postinfection. Infection
with either M. ulcerans strain elicited a mycobacterium-speciﬁc
Th1 cell response, with the number of IFN--producing cells
being signiﬁcantly higher in mice infected with the highly vir-
ulent strain (Fig. 4B). Thus, we conclude that a transient M.
ulcerans-speciﬁc, IFN--producing T-cell response occurs in
the DLN at the early phase of footpad infection, regardless the
secretion of mycolactone.
During infection with toxigenic M. ulcerans, CD4 T cells
are early recruited to the footpad but later are depleted. De-
spite the development of speciﬁc Th1 responses, M. ulcerans
98-912 is not controlled in infected footpads (Fig. 1), raising
the possibility of a deﬁcient T-cell recruitment. To address this,
we analyzed the dynamics of T-cell migration from the DLN to
the primary focus of infection. We therefore determined the
expression of CXCL9, CXCL10, and CXCL11 in infected foot-
pads, chemokines associated with trafﬁcking of Th1 cells (36).
Infection with either M. ulcerans strain induced the expression
of these chemokines, with the highly virulent strain triggering
a higher expression early during infection (Fig. 5A to C). Pre-
ceding the ulceration of footpads infected with strain 98-912,
the expression of those chemokines dropped sharply (Fig. 5A
to C). These results suggest that the setting for the recruitment
of T cells is not impaired early during infection with either
strain of M. ulcerans.
Alternatively, the lack of protection against the highly viru-
lent strain could be associated with the local destruction of
inﬁltrating lymphocytes (35) due to the cytotoxicity of myco-
lactone. Therefore, we determined the number of total and
CD4 T cells in footpads. A steady increase in the total cell
number was observed throughout the period of infection with
strain 5114, but not with 98-912 (Fig. 5D). Infection with the
mycolactone-negative strain led to a signiﬁcant increase in the
CD4 population during the ﬁrst 15 days (Fig. 5E). CD4 cells
were found at the focus of infection with strain 98-912 but, as
infection progressed, a marked decrease was observed (Fig.
5E), correlating with the emergence of ulceration. These data
FIG. 1. Lymphocytes are protective against infection with a low-virulence strain but not with a highly virulent strain of M. ulcerans. Wild-type
(f), Rag2/ (), or nude () mice were subcutaneously infected in the footpads with 3  105 AFB of M. ulcerans 5114 (A and C) or 98-912
(B and D). At different time points, the infected footpads were collected and homogenized for bacterial load determination by AFB counting. The
data points represent the means
 the standard errors of the mean (SEM) (n 5). The results of one experiment representative of two are shown.
The statistical signiﬁcance was calculated using the Student t test, comparing wild-type and immunodeﬁcient mice (***, P  0.001).
VOL. 79, 2011 M. ULCERANS INDUCES T-CELL ACTIVATION 423
 on January 3, 2012 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
show that, although the recruitment of DLN-differentiated T
cells to the footpad occurs at early time points, the inﬁltrating
cells are later destroyed at the site of infection by the myco-
lactone-producing strain.
Later during infection by the highly virulent strain of M.
ulcerans, the DLN are colonized and destroyed by apoptotic
cell death. The rapid decrease in the number of T cells in the
DLN (Fig. 2B, D, and E) may also contribute to the lack of
protection. Supporting this hypothesis, DLN histological
analysis (Fig. 6) revealed that progression of infection with
M. ulcerans 98-912, as well as with the mycolactone-positive
strains 94-1327 or 97-1116, was accompanied by severe dam-
age, with extensive areas of apoptotic and necrotic cellular
alterations, leading to the destruction of the lymphoid tis-
sue, before the onset of ulceration (Fig. 6G, H, K, L, O, and
P). In contrast, no relevant alterations were observed in the
structure of the DLN during infection with the mycolactone-
negative strain (Fig. 6A to D).
FIG. 2. Infection with M. ulcerans induces an early increase in the DLN CD4 population, followed by a sharp decrease in the case of the highly
virulent strain. Mice were subcutaneously infected in the footpad with 3  105 AFB of M. ulcerans 5114 (E) or 98-912 (F). At different time points
postinfection, the total number of leukocytes in the DLN of the infected footpad was determined (A), and the frequencies of CD3 (B), CD19
(C), CD4 (D), and CD8 (E) cells were determined by ﬂow cytometry. The data points represent the means 
 the SEM (n  5) of four
independent experiments. The statistical signiﬁcance was calculated using the Student t test, comparing each time point with noninfected mice (*,
P  0.05; **, P  0.01; ***, P  0.001).
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Previous reports showed that mycolactone-mediated cyto-
toxicity is associated with apoptotic cell death (4, 18, 35) in-
volving caspase-3 activation (56). We therefore determined the
number of cells with active caspase-3 in the DLN by day 15
postinfection. We found an increased number of active
caspase-3-positive cells in mice infected with strain 98-912,
compared to the mycolactone-negative strain (Fig. 6Q). This
increase is associated with tissue destruction and was accom-
panied by a local increase in bacterial burden, in contrast to
DLN infected with M. ulcerans 5114 (Fig. 6R). These results
show that virulent mycolactone-producing strains progressively
infect the DLN, inducing massive apoptosis-mediated cell de-
struction, further compromising a sustained T-cell response.
Infection with the highly virulent strain of M. ulcerans does
not induce systemic immunosuppression. The occurrence of
both local and systemic immunosuppression, in association
with a compromised CD4 T-cell response, has been suggested
both in BU patients and in animal models (11, 19–21, 25, 75).
After showing that local and regional immunosuppression
eventually ensues by depletion of T cells, we addressed the
occurrence of systemic immunosuppression. For this, M. ulcer-
ans-infected mice were systemically coinfected with a sublethal
dose of L. monocytogenes, when footpad lesions were already
at an advanced stage. L. monocytogenes is a facultative intra-
cellular pathogen for which the host requires CD4 and CD8
T-cell-mediated immunity for protection (5, 33, 37, 47). In fact,
it has been shown that the selective depletion of CD4 or
CD8 cells or both renders mice more susceptible to a suble-
thal dose of L. monocytogenes (47). In addition, nude or SCID
mice, although resistant to L. monocytogenes at early time
points, ultimately succumb to infection (5, 33). Therefore, this
model of coinfection will allow us to determine whether M.
ulcerans infection induces systemic immunosuppression. Our
data show that infection with M. ulcerans did not render mice
more susceptible to the coinfection, as assessed by bacterial
FIG. 3. Early development of antigen-speciﬁc CD4 T-cell re-
sponses in the DLN during infection with M. ulcerans. OVA-speciﬁc
TCR transgenic cells (KJ1.26) from DO11.10 mice were intrave-
nously transferred to noninfected mice (o) or mice subcutaneously
infected for 7 days in the footpad with 3 105 AFB of M. ulcerans 5114
() or 98-912 (f). These mice were challenged subcutaneously 2 days
later in the infected footpad with OVA. Three days after cognate
antigen challenge, the total number of cells in the DLN was calculated.
The frequencies of CD4 OVA-speciﬁc cells (A), CD4
CD62LlowOVA-speciﬁc cells (B), and CD4 BrdU OVA-specﬁc cells
(C) were determined by ﬂow cytometry. The data points represent
means 
 the SEM (n  5). The results of one experiment represen-
tative of three total experiments are shown. The statistical signiﬁcance
was calculated using the Student t test (*, P  0.05).
FIG. 4. IFN- is produced by antigen-speciﬁc T cells in the DLN
early during M. ulcerans infections. Mice were either not infected or
were subcutaneously infected in the footpad with 3  105 AFB of M.
ulcerans 5114 (E or white bars) or 98-912 (F or black bars). (A) At
different times postinfection, mRNA for IFN- was determined in the
DLN by real-time PCR. The data points represent the means 
 the
SEM (n  5) for each time point. One representative experiment of
four is shown. Statistical signiﬁcance was calculated using the Student
t test, comparing each time point with noninfected mice. (B) The
number of Ag85-speciﬁc IFN--producing T cells was determined in
the DLN by ELISPOT assay, 14 days after infection. The data points
represent the means 
 the SEM (n  4). The results of one experi-
ment representative of two total experiments are shown. Statistical
signiﬁcance was calculated by using the Student t test (*, P  0.05; **,
P  0.01; ***, P  0.001).
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counts of L. monocytogenes in both the spleen and liver (Fig.
7). These results show that the late local and regional immu-
nosuppression occurring during active infection with a virulent
mycolactone-producing M. ulcerans strain is not accompanied
by a systemic suppression of CMI.
DISCUSSION
The initiation of a protective immune response against in-
tracellular pathogens requires the activation and migration of
antigen-presenting cells to the DLN to achieve T-cell priming
(45, 73). Mycolactone has been reported to inhibit macrophage
responses (4, 12, 40, 44, 54, 65, 67), the maturation and/or
migration of dendritic cells, and consequently T-cell priming
(11). Moreover, it has been recently reported that mycolactone
injected subcutaneously or produced during experimental M.
ulcerans infection was detected in lymphoid organs and in
blood mononuclear cells. In addition, this diffusion of myco-
lactone was associated with decreased production of IL-2 by
circulating lymphocytes (25). As a consequence, it has been
suggested that M. ulcerans infections induce anergy and sys-
temic immunosuppression (11, 19–21, 25, 75).
By experimentally infecting immunodeﬁcient mice, we show
here that T cells are involved in the control of infection by a
low-virulence M. ulcerans strain but eventually are not effective
against a highly virulent mycolactone-producing strain. Never-
theless, infection with M. ulcerans 98-912, and the consequent
production of mycolactone, did not inhibit the development of
an OVA-speciﬁc response in the DLN, showing that antigen
presentation and T-cell priming is not impaired. In addition,
we showed that at the initial phase of infection, expression of
IFN- and development of mycobacterium-speciﬁc IFN--pro-
ducing T cells occurred in the DLN. In fact, infection with
highly virulent, mycolactone-producing M. ulcerans triggered a
stronger T-cell response in comparison to a low virulent,
mycolactone-negative strain, which may be related to a stron-
ger inﬂammatory stimulus associated with the higher bacterial
load. The occurrence of an initial adaptive CMI immune re-
sponse in the DLN is in accordance with the resistance to M.
ulcerans infection being associated with IFN- production in
humans (20, 21, 42, 48, 70, 72) and in experimental infections
(61, 67) and with the concept that M. ulcerans is an intracel-
lular pathogen (53, 66).
Moreover, the CD4 T cells activated in the DLN of mice
infected with either M. ulcerans strains migrate to the periph-
eral infectious focus, mobilized by Th1-recruiting chemokines.
However, while CD4 T cells persist in the focus of infection
with the low-virulence strain, they are progressively depleted
during infection with strain 98-912, correlating with extensive
leukocyte apoptosis and tissue necrosis (35). This depletion of
CD4 T cells in the footpad was already observed at day 15
postinfection, when their numbers in the DLN were still in-
FIG. 5. Early recruitment followed by depletion of CD4 cells in the footpad during infection with highly virulent M. ulcerans. Mice were
subcutaneously infected in the footpad with 3  105 AFB of M. ulcerans 5114 (E or white bars) or 98-912 (F or black bars). (A to C) At speciﬁc
time points, RNA was extracted from a single cell suspension of the footpad. The presence of speciﬁc mRNAs for CXCL9, CXCL10, and CXCL11
were determined by real-time PCR. The data points represent the means 
 the SEM (n  5) for each time point. The results are from one
experiment representative of two separate experiments (*, P  0.05; **, P  0.01; ***, P  0.001). (D and E) Tissue sections of the footpad were
stained with DAPI (D) and anti-CD4 (E). The average number of DAPI or CD4 cells per footpad was determined by using a 40 objective
lens. The data points represent the means 
 the SEM (n  4). The results are from one experiment representative of two independent
experiments.
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FIG. 6. Late apoptotic destruction of the DLN in mice infected with highly virulent M. ulcerans is associated with a higher bacterial
burden. The DLN of mice subcutaneously infected in the footpad with 3  105 AFB of M. ulcerans 5114 (A to D), 94-1327 (E to H), 97-1116
(I to L), or 98-912 (M to P) were harvested at day 10 (A, E, I, and M), 15 (B and N), 20 (F, J, O, and P), 50 (K and L), and 60 (C, D, G,
and H). Tissue sections were stained with H&E. The images are representative of ﬁve lymph nodes per group analyzed in four independent
experiments. For panels A to C, E to G, I to K, and M to O, the scale bars represent 500 m. For panels D, H, L, and P, the scale bars
represent 20 m. (Q) The DLN of noninfected mice (dashed bar) or mice infected with M. ulcerans 5114 (white bar) or 98-912 (black bar)
were harvested at day 15. Apoptotic cells were labeled by immunoﬂuorescence for activated caspase 3. The average number of activated
caspase 3 cells/LN was determined by using a 20 objective lens. The data points represent the means 
 the SEM (n  4). The results
are from one of two independent experiments. (R) The bacterial burden of DLN of mice infected with M. ulcerans 5114 (white bars) or
98-912 (black bars) was determined over time by CFU counts. Dashed line represents the detection limit. The data points represent the
means 
 the SEM (n  5). The results are from one of two separate experiments. Statistical signiﬁcance was calculated using the Student
t test (**, P  0.01; ***, P  0.001).
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creasing, which is likely due to an earlier accumulation of
mycolactone at the initial site of infection.
Collectively, our results show that the early recruitment of T
cells to the primary site of infection is not compromised by
infection with high virulent M. ulcerans; however, in time this
potentially protective response is abrogated by local and re-
gional suppression of CMI. The lack of a sustained adaptive
immune response to virulent M. ulcerans may have the contri-
bution of other factors, namely, (i) mycolactone-mediated in-
hibition of antimycobacterial mechanisms in IFN--activated
macrophages (67), (ii) mycolactone-induced dysregulation of
intracellular signaling pathways coupled to TCR activation (6),
and (iii) vascular pathology with occlusion of vessels as occurs
in progressive BU lesions (23, 29, 53, 71).
By the end of the experimental infection with the mycolac-
tone-positive strain, we observed a decrease in the total num-
ber of cells in the DLN. This local/regional cytotoxic effect of
mycolactone does not seem to be speciﬁc for T cells, since B
cells were equally affected. This tissue destruction of lymph
nodes was associated with bacterial colonization, which is con-
sistent with the spreading of M. ulcerans from the site of in-
fection to the lymph nodes via afferent lymphatic drainage (3,
12, 74). Lymphadenopathy in BU patients has been seldom
appreciated; however, there is a description of lymph node
destruction and bacterial colonization (74), conﬁrming our ex-
perimental results. The continuous lymphatic dissemination of
M. ulcerans, either freely or shuttled in phagocytes, could ex-
plain the high recurrence rates after surgical intervention alone
(8, 34, 46), as well as cases of disseminated BU (1, 9, 24, 43,
57). Our results highlight the importance of investigating
lymph node involvement in BU patients and considering the
impact of possible bacterial colonization during treatment
procedures, further reinforcing the importance of antibiotic
therapy.
Previous studies have suggested that M. ulcerans infection
leads to the occurrence of systemic anergy/immunosuppres-
sion. This interpretation was mainly based on reports of lack of
response of antigen-speciﬁc peripheral blood mononuclear
cells from active BU patients upon speciﬁc stimuli (19–21, 42,
75). Mycolactone was further implicated in this status of pe-
ripheral anergy/immunosuppression, when the toxin was de-
tected in lymphoid organs and in blood mononuclear cells
during an experimental subcutaneous infection with M. ulcer-
ans (25). However, our observation of DLN destruction, with
consequent depletion of T cells, could explain the lack of
speciﬁc T-cell responses reported in the periphery. Moreover,
we show that progressive, advanced infection with M. ulcerans
did not render mice more susceptible to a systemic coinfection
with L. monocytogenes, an infection for which the host requires
T-cell-mediated immunity for protection (5, 33, 37). This fur-
ther supports our interpretation that the local and regional
destruction of immune cells that occurs during M. ulcerans
infection is not associated with systemic immunosuppression.
This is in line with BU patients not having an increased sus-
ceptibility to opportunistic infections and with cutaneous BU
being associated with minimum systemic effects (70).
The lack of knowledge about the amount of cytotoxic factors
released from M. ulcerans during the early or late stages of
active infection has already been discussed (53), but our
present data suggest that, although mycolactone might reach
peripheral organs, its biological activity is probably limited to
sites where its concentration is enough to produce cytopathol-
ogy (53).
In addition to mycolactone, other macrolides have been
described as immunosuppressors. FK605 is an immunosup-
pressive macrolide mainly used to lower the risk of allogeneic
transplant rejection by inhibiting T-cell signal transduction and
interleukin-2 transcription (30) and by affecting dendritic cell
differentiation and function (2, 22). Although FK506 is struc-
turally similar to mycolactone, it has been suggested that the
mechanisms underlying mycolactone’s suppressive activity are
different and that this speciﬁcity of action may deﬁne a novel
class of immunosuppressive agents (11). However, our obser-
vations do not support a systemic immunosuppressive effect of
mycolactone, at least with the amounts produced during a
footpad M. ulcerans infection.
The ﬁndings reported here contribute to foster our under-
standing of BU pathogenesis and have important implications
for the design of new prophylactic/therapeutic strategies. In-
deed, our data suggest that early antibiotic treatment is essen-
tial to prevent the compromise of the early development of
IFN--mediated CMI. Furthermore, our results prompt the
development of improved vaccines that would boost this type
of adaptive antibacterial immunity, leading to an early recall
FIG. 7. Subcutaneous footpad infection with a highly virulent strain
of M. ulcerans does not increase the susceptibility to a systemic coin-
fection with L. monocytogenes. Mice were either left uninfected (‚) or
subcutaneously infected in the footpad with 3  105 AFB of M. ulcer-
ans 5114 (E) or 98-912 (F). During the fourth week of infection, when
the infected footpad showed evidence of advanced swelling, mice were
intravenously infected with 5  103 CFU of L. monocytogenes. The
spleens and livers were harvested, and the bacterial burden (CFU
counts) was determined over time. The dashed line represents the
detection limit. The data points represent the means 
 the SEM (n 
5). The results are from one experiment representative of two separate
experiments.
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immune response before the build-up of mycolactone compro-
mises the T-cell differentiation and persistence.
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